Robert Howard, Rupert McShane, James Lindesay, Craig Ritchie et al.
BACKGROUND: Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-moderate Alzheimer's disease. It is not known whether treatment benefits continue after the progression to moderate-to-severe disease. METHODS: We assigned 295 community-dwelling patients wh...
Md. Sahab Uddin, Anna Stachowiak, Abdullah Al Mamun, Nikolay Tzvetkov et al.
Alzheimer’s disease (AD) is the most common cause of progressive dementia in the elderly. It is characterized by a progressive and irreversible loss of cognitive abilities and formation of senile plaques, composed mainly of amyloid β (Aβ), and neurofibrillary tangles (NFTs), composed of tau protein,...
Sabine Ring, Sascha W. Weyer, Susanne B. Kilian, Elaine Waldron et al.
It is well established that the proteolytic processing of the beta-amyloid precursor protein (APP) generates beta-amyloid (Abeta), which plays a central role in the pathogenesis of Alzheimer's disease (AD). In contrast, the physiological role of APP and of its numerous proteolytic fragments and the ...
L.T. McGrath
Oxidative stress is thought to play a major role in the pathogenesis of Alzheimer's disease (AD). Although there is strong post-mortem and experimental evidence of oxidative damage occurring in AD brains, the use of markers in the peripheral circulation to show oxidative stress is less convincing. W...
Joseph Butchart, Laura Brook, Vivienne Hopkins, Jessica L. Teeling et al.
OBJECTIVES: To determine whether the tumor necrosis factor α inhibitor etanercept is well tolerated and obtain preliminary data on its safety in Alzheimer disease dementia. METHODS: In a double-blind study, patients with mild to moderate Alzheimer disease dementia were randomized (1:1) to subcutaneo...
Md. Sahab Uddin, Md. Tanvir Kabir, Abdullah Al Mamun, Mohamed M. Abdel‐Daim et al.
Alzheimer's disease (AD) is an immutable neurodegenerative disease featured by the two hallmark brain pathologies that are the extracellular amyloid ß (Aß) and intraneuronal tau protein. People carrying the APOE4 allele are at high risk of AD concerning the ones carrying the ε3 allele, while the ε2 ...
Md. Tanvir Kabir, Md. Sahab Uddin, Abdullah Al Mamun, Philippe Jeandet et al.
Alzheimer's disease (AD) is the leading cause of dementia worldwide. Even though the number of AD patients is rapidly growing, there is no effective treatment for this neurodegenerative disorder. At present, implementation of effective treatment approaches for AD is vital to meet clinical needs. In ...
Md. Habibur Rahman, Rokeya Akter, Tanima Bhattacharya, Mohamed M. Abdel‐Daim et al.
Alzheimer’s disease (AD) is a progressive cortex and hippocampal neurodegenerative disease which ultimately causes cognitively impaired decline in patients. The AD pathogen is a very complex process, including aggregation of Aβ (β-amyloid peptides), phosphorylation of tau-proteins, and chronic infla...
Md. Sahab Uddin, Devesh Tewari, Abdullah Al Mamun, Md. Tanvir Kabir et al.
Alzheimer's disease (AD) is a devastating and irreversible cognitive impairment and the most common type of dementia. Along with progressive cognitive impairment, dysfunction of the circadian rhythms also play a pivotal role in the progression of AD. A mutual relationship among circadian rhythms, sl...
Rashita Makkar, Tapan Behl, Simona Bungău, Gökhan Zengin et al.
Neurological diseases are one of the major healthcare issues worldwide. Posed lifestyle changes are associated with drastically increased risk of chronic illness and diseases, posing a substantial healthcare and financial burden to society globally. Researchers aim to provide fine treatment for aili...
Md. Sahab Uddin, Devesh Tewari, Gaurav Sharma, Md. Tanvir Kabir et al.
Alzheimer's disease (AD) is a progressive neurodegenerative disease involving aggregation of misfolded proteins inside the neuron causing prolonged cellular stress. The neuropathological hallmarks of AD include the formation of senile plaques and neurofibrillary tangles in specific brain regions tha...
MdSahab Uddin, GhulamMd Ashraf, AbdullahAl Mamun, Bijo Mathew
Alzheimer's disease is characterized by the extracellular accumulation of the amyloid β in the form of amyloid plaques and the intracellular deposition of the microtubule-associated protein tau in the form of neurofibrillary tangles. Most of the Alzheimer's drugs targeting amyloid β have been failed...
Md. Shahazul Islam, Cristina Quispe, Rajib Hossain, Muhammad Torequl Islam et al.
animal experiments and human trials. QUR protects the organism against neurotoxic chemicals and also can prevent the evolution and development of neuronal injury and neurodegeneration. The present work aimed to summarize the literature about the neuroprotective effect of QUR using known database sou...
Qian Zhou, Ying Zhang, Lu Lu, Hu Zhang et al.
The epidemiological correlation between copper exposure and higher risk of Parkinson disease (PD) has been recognized for a long time, and microglia-mediated neuroinflammation has reported to be an important component of the pathogenesis of PD. The present study aimed to investigate the role of micr...
Angela M. Bodles, David J. S. Guthrie, Brett Greer, G. Brent Irvine
The non-beta-amyloid (Abeta) component of Alzheimer's disease amyloid (NAC) and its precursor alpha-synuclein have been linked to amyloidogenesis in several neurodegenerative diseases. NAC and alpha-synuclein both form beta-sheet structures upon ageing, aggregate to form fibrils, and are neurotoxic....